IVDR (EU 2017/746) is the European Union regulation governing the design, manufacture, and market placement of in vitro diagnostic (IVD) devices sold in EU member states. It replaced Directive 98/79/EC, introduced risk-based classification from Class A to Class D, and requires notified body assessment for most device classes before a CE mark is issued.
What is IVDR (EU 2017/746)?
IVDR (EU 2017/746) is the regulatory framework in vitro diagnostic manufacturers must follow to place devices on the EU market. It sits at the center of the IVD product lifecycle: classification happens early in design, technical documentation accumulates through verification and validation, and post-market obligations continue for as long as the device stays on the market. The regulation became fully applicable on May 26, 2022, after transitional deadlines extended compliance timelines for devices already certified under the old directive.
IVDs carry real clinical risk, sometimes greater than the therapeutic devices they inform decisions about. Under Directive 98/79/EC, roughly 80 percent of IVDs could self-certify with no notified body involvement. IVDR flips that ratio: most devices now need third-party conformity assessment, and manufacturers must generate stronger evidence to support their intended use claims.
Why IVDR (EU 2017/746) matters in medical device development
Get IVDR wrong, and a device cannot enter the EU market, no matter how strong the underlying science is. Classification often lands a device in a higher risk class than it would have received under the old directive, particularly for blood screening, companion diagnostics, or self-testing products. A higher class pulls in notified body review, extending timelines by months and adding cost for studies that were not previously required. Programs that budget compliance late, after design freeze, tend to discover evidence gaps that force rework.
Patient safety is the other half of the stakes. IVD results drive treatment decisions directly, from cancer companion diagnostics to infectious disease screening. A device that performs poorly in the field creates diagnostic errors with downstream clinical consequences, not just a business problem. IVDR’s surveillance and vigilance requirements exist to catch that kind of drift after launch.
How IVDR (EU 2017/746) works
IVDR organizes the path to market around a few connected pillars.
- Classification (Annex VIII). Seven rules sort devices into Class A, B, C, or D by risk to patients and public health, factoring in self-testing, near-patient use, or the harm an incorrect result could cause.
- General safety and performance requirements (Annex I). Baseline requirements covering design, manufacturing, labeling, and information for use.
- Performance evaluation. A report covering scientific validity, analytical performance, and clinical performance, replacing the lighter evidence expected under the old directive.
- Technical documentation (Annexes II and III). A structured technical file plus post-market surveillance documentation, maintained for the device’s life.
- Notified body assessment. Required for Class B, C, and D devices, with some exceptions, covering the QMS and technical documentation for higher classes.
- UDI and EUDAMED. A Unique Device Identifier plus registration of the device, manufacturer, and certificates in the EU database.
- PRRC. Every manufacturer names a Person Responsible for Regulatory Compliance with defined qualifications.
- Post-market surveillance. Ongoing PMS plans, periodic safety update reports for higher-risk classes, and vigilance reporting for incidents and field safety corrective actions.
A quality management system aligned to ISO 13485 underpins all of it. Notified bodies audit it as part of certification, not just review it on paper.
Common challenges and best practices
The most common mistake is treating IVDR as a labeling exercise instead of a design input. Classification should happen early because it determines the entire evidence burden downstream. Teams that wait until they have a finished device often find they need clinical performance studies that should have been planned into the timeline.
Notified body capacity is a real constraint. Demand has outpaced capacity for years, and slots book out well in advance. Manufacturers who submit early tend to fare better than those who wait for a deadline.
Performance evaluation is frequently underestimated. Analytical data alone is not enough; reviewers expect a genuine study-based case for clinical performance, tied to the specific intended use and population. Vague intended use statements invite extra questions.
Legacy devices transitioning from the old directive need their own plan. Extended deadlines give more runway, but only for devices that already hold a valid certificate and meet specific conditions; new and significantly changed devices do not benefit.
Good practice: decide classification before design freeze, scope the performance evaluation plan alongside the design plan, close PRRC and QMS gaps before a notified body audit, and track EUDAMED registration as a project milestone.
How SJML helps with IVDR (EU 2017/746)
SJML supports IVD programs through the IVDR pathway as part of its regulatory affairs and compliance services, including regulatory strategy and device classification, technical file development, clinical evaluation support, and post-market surveillance planning. SJML also assists with EUDAMED-related and international registration alongside EU MDR and IVDR filings, working from a quality management system aligned to ISO 13485. SJML’s QARA team helps close documentation and evidence gaps ahead of notified body submission.
Frequently asked questions
IVDR stands for In Vitro Diagnostic Regulation, formally EU Regulation 2017/746. It is the legal framework governing in vitro diagnostic devices placed on the EU market, covering classification, clinical evidence, labeling, and post-market surveillance.
IVDR became fully applicable on May 26, 2022. An amending regulation later extended transitional deadlines for legacy devices already certified or self-declared under the previous IVD Directive, with staggered dates by risk class, but new devices had to comply from the original date.
IVDR replaced Directive 98/79/EC and shifted most devices from self-certification to notified body oversight. It introduced formal risk-based classification, stronger evidence requirements, UDI labeling, and the EUDAMED database, none of which existed in the same form before.
Class B, C, and D devices generally require notified body assessment, with review depth increasing by class. Class A devices supplied in sterile condition also require limited notified body input for the sterility claim; most other Class A devices can still self-certify.
A performance evaluation report is the document set showing a device meets its performance claims, built from scientific validity, analytical performance, and clinical performance. It underpins the technical file and is reviewed by the notified body for Class B, C, and D devices.
Related terms
- Performance Evaluation Report
- Notified Body
- Unique Device Identifier (UDI)
- EU MDR (2017/745)
- Post-Market Surveillance Plan
